Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria

Current Opinion in Critical Care
Matteo BassettiMaddalena Peghin

Abstract

Describe the risk factors and discuss the management of multidrug-resistant (MDR) bacteria responsible for pneumonia among critically ill patients, including methicillin-resistant Staphylococcus aureus, extended spectrum beta-lactamase-producing Enterobactericeae, carbapenem-resistant Enterobactericeae, multidrug resistant Pseudomonas aeruginosa, and Acinetobacter baumannii. Multiple factors have been associated with infections because of MDR bacteria, including prolonged hospital stay, presence of invasive devices, mechanical ventilation, colonization with resistant pathogens, and use of broad-spectrum antibiotics. Management of these infections includes the prompt use of appropriate antimicrobial therapy, implementation of antimicrobial stewardship protocols, and targeted active microbiology surveillance. Combination therapy and novel molecules have been used for the treatment of severe infections caused by resistant bacteria. The exponential increase of antimicrobial resistance among virulent pathogens currently represents one of the main challenges for clinicians in the intensive care unit. Knowledge of the local epidemiology, patient risk stratification, and infection-control policies remain key elements for the management...Continue Reading

References

Apr 6, 2002·American Journal of Respiratory and Critical Care Medicine·Jean Chastre, Jean-Yves Fagon
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elisabeth ParamythiotouAntoine Andremont
Mar 27, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·K M C VerhammeP Jordens
Sep 22, 2007·The Journal of Antimicrobial Chemotherapy·Matthew E FalagasArgyris Michalopoulos
Nov 17, 2007·Nature Reviews. Microbiology·Lenie DijkshoornHarald Seifert
Jun 17, 2008·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Laura de Andrade da RochaPaulo Gontijo Filho
Mar 17, 2009·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Michel R MoreiraPaulo P Gontijo Filho
Dec 25, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M MonteroH Knobel
May 27, 2010·Scandinavian Journal of Infectious Diseases·Murat DizbayKenan Hizel
Jun 29, 2010·Current Opinion in Infectious Diseases·José Garnacho-Montero, Rosario Amaya-Villar
Jul 22, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Wang-Huei ShengShan-Chwen Chang
Oct 27, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L Paterson, Benjamin A Rogers
Jul 22, 2011·The Journal of Antimicrobial Chemotherapy·Carla J WalravenRenée-Claude Mercier
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Jan 10, 2012·The Journal of Hospital Infection·E BouzaUNKNOWN Gregorio Marañón Task Force for Pneumonia (GANG)
Jan 17, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard G WunderinkJean Chastre
Jun 19, 2012·Expert Review of Anti-infective Therapy·Matteo BassettiPaolo Pelosi
Jul 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mario TumbarelloMatteo Bassetti
Nov 2, 2012·Scandinavian Journal of Infectious Diseases·Astra VitkauskieneRaimundas Sakalauskas
Mar 26, 2013·Current Opinion in Pulmonary Medicine·François BarbierLila Bouadma
Apr 26, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emanuele Durante-MangoniRiccardo Utili
Jul 17, 2013·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·Renato SeligmanElyara Fiorin Pacheco
Aug 7, 2013·Antimicrobial Agents and Chemotherapy·Oren ZusmanMical Paul
Nov 28, 2013·Antimicrobial Agents and Chemotherapy·Benjamin DangerfieldMaria Teresa Seville
Mar 29, 2014·The New England Journal of Medicine·Shelley S MagillUNKNOWN Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team
Apr 12, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Samir S AwadMarc Engelhardt
Apr 16, 2014·Antimicrobial Agents and Chemotherapy·Mario TumbarelloPierluigi Viale
May 30, 2014·The Journal of Antimicrobial Chemotherapy·Mical PaulLeonard Leibovici
Jun 4, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L S TzouvelekisG L Daikos
Jul 2, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M GiannellaM Tumbarello
Nov 29, 2014·BMC Infectious Diseases·José Garnacho-MonteroLuis Martin-Villen
Dec 3, 2014·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Tai-Chin HsiehWen-Sen Lee

❮ Previous
Next ❯

Citations

Jan 24, 2019·Expert Review of Anti-infective Therapy·Jan J De Waele, Sofie Dhaese
Jan 17, 2019·Current Opinion in Infectious Diseases·Paola Del GiacomoMario Tumbarello
Oct 1, 2019·Current Opinion in Infectious Diseases·Almudena BurilloEmilio Bouza
Jul 14, 2020·Virusdisease·Salvatore Chirumbolo, Geir Bjørklund
Aug 8, 2020·European Respiratory Review : an Official Journal of the European Respiratory Society·Maria Sole VallecocciaGennaro De Pascale
Oct 6, 2020·Frontiers in Pharmacology·Cuicui Lu, Ning Hou
May 2, 2019·Frontiers in Medicine·Matteo BassettiDaniele Roberto Giacobbe
Jun 15, 2019·Journal of Burn Care & Research : Official Publication of the American Burn Association·Eng-Kean Yeong, Wei-Lieh Huang
Sep 26, 2019·Expert Review of Anti-infective Therapy·Daniele Roberto GiacobbeMatteo Bassetti
Jul 1, 2020·Critical Care : the Official Journal of the Critical Care Forum·Rafael ZaragozaIgnacio Martín-Loeches
Oct 9, 2019·Expert Opinion on Emerging Drugs·Matteo BassettiMark Wilcox
Nov 11, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Jordi RelloUNKNOWN Nine-I study Group
Jun 21, 2020·Critical Care : the Official Journal of the Critical Care Forum·Nathan Peiffer-SmadjaLaurence Armand-Lefevre
Aug 3, 2020·Current Opinion in Critical Care·Adrian John Brink, Guy Richards
Jan 7, 2020·Current Opinion in Anaesthesiology·Jan J De WaeleIsabel Leroux-Roels
Feb 18, 2021·Expert Review of Anti-infective Therapy·Alessandro RussoMatteo Bassetti
Apr 10, 2021·Antimicrobial Resistance and Infection Control·Marianna MeschiariCristina Mussini
Apr 10, 2021·Nature Reviews. Disease Primers·Antoni TorresTom van der Poll
Oct 14, 2019·Anaesthesia Critical Care & Pain Medicine·Marc LeoneBoris Jung
May 11, 2021·FEMS Microbiology Reviews·Andreu Coello PelegrinAlex van Belkum
Aug 20, 2021·Frontiers in Medicine·Alessandro RussoMatteo Bassetti
Jan 19, 2022·Seminars in Respiratory and Critical Care Medicine·Di Pan, Michael S Niederman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.